Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Calls Off Transfer of Innovative Drugs after Global Split Plan Scrapped
November 4, 2016
- Mitsubishi Tanabe Licenses Cell Therapy Agent for Knee Osteoarthritis from S. Korean Firm
November 4, 2016
- Mitsubishi Tanabe Ekes Out Sales Rise on Simponi, Other Major Products
November 2, 2016
- Harvoni Top-Seller Drug in Japan in July-September: QuintilesIMS
November 2, 2016
- Strong Yen Dampens Sales of 4 Japanese Majors, but Global Brands Keep Up Momentum
November 2, 2016
- HER2-Targeting ADC Is One of Our Top Priorities: Daiichi Sankyo CEO
November 2, 2016
- Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
November 2, 2016
- Shionogi Shooting for New Product Sales of 200 Billion Yen in FY2020
November 2, 2016
- Takeda Establishes Drug Discovery Company in New York in Partnership with US Research Institutions
November 2, 2016
- Hisaharu Hirai Named as Japan Vaccine Chairman
November 2, 2016
- Merck Serono Aims to Get Japan Nod for Avelumab in 2017: Pres. Lee
November 2, 2016
- Takeda Mum on Kaketsuken Biz Transfer; CEO Says He Needs to Better Understand Situation
November 1, 2016
- MSD Files Japan NDA for Bezlotoxumab for C. Difficile Infection
November 1, 2016
- Pfizer Seeks Japan Approval of Breast Cancer Drug Palbociclib
November 1, 2016
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
November 1, 2016
- Nichi-Iko Wins Patent Suit over Elplat
November 1, 2016
- Shionogi Nets 12.2% Sales Rise on HIV Med Royalty Revenues
November 1, 2016
- Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
- Keytruda “Will Be Able to Contribute to 1st-Line Treatment” of NSCLC: MSD Official
November 1, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…